@entity26742 , a novel soluble @entity935 D2 agonist in the treatment of XXXX .

@entity1 @entity26742 @entity390 @entity304 @entity935 @entity391 @entity191
@entity26742 , a novel aminotetralin @entity935 D2 agonist, was shown to effectively reverse @entity304 in nine dopa/agonist-responsive @entity191 @entity1 . The drug was given up to 4.5 hours by continuous intravenous (i.v.) infusion using an i.v. pump. The onset of anti- @entity191 effect was seen within minutes of the initiation of the infusion and was absent within 90 minutes of cessation of the infusion. The short elimination half-life of @entity26742 (90 min) would allow for the rapid initiation of drug effect when necessary and at the same time permit the effect to be terminated quickly if necessary. The drug would be useful in situations where oral medication is not feasible or is associated with erratic absorption. The @entity1 tolerated the drug well. Dose escalation load was limited by @entity390 and @entity391 . It should be noted that the doses were increased until these symptoms occurred, but therapeutic effects were noted well before the side effects occurred. Using a modified Columbia scale, maximum improvement consisted of a 27-95% drop in score. Maximum response was obtained at infusion rates varying from 2-16 microg/kg per hour and at blood levels of 0.11-1.49 microg/mL.
